Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

Summary

This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.

Timeline

Start

2023-06-23

Primary completion

2024-05-01

Completion

2025-06-01

Outcome

Met primary endpoint

release “Primary and Secondary Endpoints Achieved with Statistical Significance” vogenx.com ↗

Drugs

Indications